T he TNM staging system of the American Joint Committee on Cancer (AJCC) staging classification, combined with other clinical and molecular findings, is the basis for making informed treatment decisions and prognostic assessment for patients with colon and rectal cancer. The current eighth edition was published in 2016 and implemented in 2018. Despite its worldwide use, the TNM has several limitations: 1) it primarily relies on anatomic/pathological characteristics of the tumor and includes very limited molecular information; 2) it does not fully capture tumor biology/heterogeneity, leading to inconsistencies in prognosis and treatment recommendations; 3) the system is complex and requires an accurate assessment of tumor characteristics; 4) it lacks clarity regarding the assessment of lymph node involvement (ie, isolated tumor cells, micrometastases, extranodal extension, and so on); 5) it only provides a snapshot of the status of the tumor at the time of diagnosis but does not take into account response to treatment or tumor progression; and 6) it does not incorporate circulating tumor markers (eg, CEA), which can provide valuable information regarding treatment response and disease progression over time.In addition, over the past 10 to 20 years, the TNM staging system has been updated several times. During Funding/Support: None reported.